Lv1
30 积分 2021-06-02 加入
The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications
6天前
已完结
Early pre-existing anti-drug antibody screening in biotherapeutic development: a cross-company perspective
24天前
已完结
Multispecific T-cell engagers attract cancer drug developers
1个月前
已完结
T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand
1个月前
已完结
Unlocking the potential of T cell engagers in solid tumors
1个月前
已完结
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
1个月前
已完结
Antibody engineering
1个月前
已完结
Boosting Natural Killer Cells’ Immunotherapy with Amoxicillin-Loaded Liposomes
2个月前
已完结
Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy
3个月前
已完结
The complex patent situation regarding antibody Fc engineering
4个月前
已完结
皖公网安备34019202002308
